Learn Before
Findings opposed to use of Chloroquine as COVID-19 intervention
Findings opposed to use of Azithromycin+Hydroxychloroquine as COVID-19 intervention
Findings opposed to use of Chloroquine + macrolide (Azithromycin or clarithromycin) as COVID-19 intervention
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Hazard ratios for in-hospital mortality among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Hazard ratios for ventricular arrhythmia among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratios for in-hospital mortality among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Hazard ratios for ventricular arrhythmia among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratios for in-hospital mortality among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Findings from a Systematic Review and Meta-Analysis on the Effect of Hydroxychloroquine With or Without Azithromycin on the Mortality of COVID-19 Patients
Hazard ratios for ventricular arrhythmia among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratios for in-hospital mortality among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratios for in-hospital mortality among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratios for ventricular arrhythmia among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20